The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.

 
Web www.patentalert.com

< Pyrrolotriazine kinase inhibitors

< Dibenzo chromene derivatives and their use as ERbeta selective ligands

> Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl- ]methoxy] benzyl]thiazolidine-2,4-dione potassium salt

> Triazaspiro compounds useful for treating or preventing pain
~ 00216